Incara Pharmaceuticals, which announced a reverse 10-for-1 stock split last week, added three new members to its board of directors on Monday.

Chris Rallis is the former president and chief operating officer of Triangle Pharmaceuticals. He also worked for Burroughs Wellcome for 13 years.

Peter Suzdak is president and CEO of Artesian Therapeutics.

Michael Lewis is president of BioDiligence Partners and also co-founded Cara Therapeutics.